[go: up one dir, main page]

WO1997018840A3 - Therapeutic delivery using compounds self-assembled into high axial ratio microstructures - Google Patents

Therapeutic delivery using compounds self-assembled into high axial ratio microstructures Download PDF

Info

Publication number
WO1997018840A3
WO1997018840A3 PCT/US1996/018850 US9618850W WO9718840A3 WO 1997018840 A3 WO1997018840 A3 WO 1997018840A3 US 9618850 W US9618850 W US 9618850W WO 9718840 A3 WO9718840 A3 WO 9718840A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic
assembled
harfm
high axial
axial ratio
Prior art date
Application number
PCT/US1996/018850
Other languages
French (fr)
Other versions
WO1997018840A2 (en
Inventor
Paul Yager
Michael H Gelb
Paul A Carlson
Anatoly N Lukyanov
Alex S Goldstein
Kyujin C Lee
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Priority to AU12738/97A priority Critical patent/AU1273897A/en
Publication of WO1997018840A2 publication Critical patent/WO1997018840A2/en
Publication of WO1997018840A3 publication Critical patent/WO1997018840A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6919—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a ribbon or a tubule cochleate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Therapeutic agents comprising plural therapeutic compounds self-assembled into high axial ration microstructures are described. The therapeutic compounds satisfy the formula HARFM-Th, wherein HARFM is a high axial ratio forming material and Th is a therapeutic associated with the HARFM. The therapeutic agent also can satisfy the formula HARFM-S-Th, wherein S is a spacer. Release of the therapeutic by the agent generally follows either 0-order kinetics or pseudo-first order kinetics. A method for delivering drugs to animals or persons also is described. The method comprises administering an effective amount of a therapeutic self-assembled into an HAR microstructure to the animal or person.
PCT/US1996/018850 1995-11-22 1996-11-21 Therapeutic delivery using compounds self-assembled into high axial ratio microstructures WO1997018840A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU12738/97A AU1273897A (en) 1995-11-22 1996-11-21 Therapeutic delivery using compounds self-assembled into high axial ratio microstructures

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2513795P 1995-11-22 1995-11-22
US60/025,137 1995-11-22

Publications (2)

Publication Number Publication Date
WO1997018840A2 WO1997018840A2 (en) 1997-05-29
WO1997018840A3 true WO1997018840A3 (en) 1997-10-09

Family

ID=21824258

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/018850 WO1997018840A2 (en) 1995-11-22 1996-11-21 Therapeutic delivery using compounds self-assembled into high axial ratio microstructures

Country Status (2)

Country Link
AU (1) AU1273897A (en)
WO (1) WO1997018840A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180114B1 (en) * 1996-11-21 2001-01-30 University Of Washington Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
WO2009074569A1 (en) * 2007-12-11 2009-06-18 Bracco International Bv Targeting and therapeutic compounds with a polyproline-comprising spacer and gas-filled microvesicles comprising said compounds
CN106083637B (en) * 2016-06-06 2018-11-23 大连民族大学 The synthetic method and its application of monosodium glutamate lipoid, monosodium glutamate liposome

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004566A (en) * 1987-02-06 1991-04-02 Geo-Centers, Inc. Process for fabrication of lipid microstructures from dry organic solvent
WO1996025942A1 (en) * 1995-02-22 1996-08-29 Albany Medical College Cochleate phospholipids in drug delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004566A (en) * 1987-02-06 1991-04-02 Geo-Centers, Inc. Process for fabrication of lipid microstructures from dry organic solvent
WO1996025942A1 (en) * 1995-02-22 1996-08-29 Albany Medical College Cochleate phospholipids in drug delivery

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ARCHIBALD, DOUGLAS DEAN ET AL: "Structural studies of lipid fibers formed by sphingosine", BIOCHIM. BIOPHYS. ACTA (1993), 1166(2-3), 154-62 CODEN: BBACAQ;ISSN: 0006-3002, 1993, XP002035252 *
CHEMICAL ABSTRACTS, vol. 119, no. 14, 4 October 1993, Columbus, Ohio, US; abstract no. 146454, SPARGO, BARRY J. ET AL: "Technological development of lipid-based microcylinders: biocompatibility and controlled release" XP002035255 *
CHEMICAL ABSTRACTS, vol. 126, Columbus, Ohio, US; abstract no. 340085, HARTGERINK, JEFFREY D. ET AL: "Self assembling organic nanotubes" XP002035256 *
ITOJIMA, YUKIKO ET AL: "Helical structures of nucleic acid - lipid conjugates: formation and morphology of helical structures from dimyristoyl-5'-phosphatidylribonucleosides", NUCLEIC ACIDS SYMP. SER. (1990), 22(SYMP. NUCLEIC ACIDS TECHNOL., 1990), 123-4 CODEN: NACSD8;ISSN: 0261-3166, 1990, XP002035254 *
ITOJIMA, YUKIKO ET AL: "Spontaneous formation of helical structures from phospholipid-nucleoside conjugates", BIOCHEMISTRY (1992), 31(20), 4757-65 CODEN: BICHAW;ISSN: 0006-2960, 1992, XP002035253 *
J.M. SCHNUR ET AL.: "Development of self-assembled lipid microcylinders for controlled release applications2", PHARM. NEWS (LANGHORNE, PA.) (1995), 2(1), 10-15 CODEN: PHNEEP;ISSN: 1071-894X, vol. 2, no. 1, 1995, pages 10 - 15, XP002035459 *
MATER. RES. SOC. SYMP. PROC. (1992), 252(TISSUE-INDUCING BIOMATERIALS), 285-91 CODEN: MRSPDH;ISSN: 0272-9172, 1992 *
NEW MACROMOL. ARCHIT. FUNCT., PROC. OUMS'95, 2ND (1996), MEETING DATE 1995, 181-188. EDITOR(S): KAMACHI, MIKIHARU;NAKAMURA, AKIRA. PUBLISHER: SPRINGER, BERLIN, GERMANY. CODEN: 64HZAA, 1996 *
PRICE R ET AL: "CONTROLLED RELEASE FROM CYLINDRICAL MICROSTRUCTURES", JOURNAL OF MICROENCAPSULATION, vol. 8, no. 3, 1 July 1991 (1991-07-01), pages 301 - 306, XP000220220 *
SPARGO, B. J. ET AL: "Controlled release of transforming growth factor-.beta. from lipid-based microcylinders", J. MICROENCAPSULATION (1995), 12(3), 247-54 CODEN: JOMIEF;ISSN: 0265-2048, 1995, XP002035251 *

Also Published As

Publication number Publication date
AU1273897A (en) 1997-06-11
WO1997018840A2 (en) 1997-05-29

Similar Documents

Publication Publication Date Title
CA2184242A1 (en) Drug Targeting System, Method for Preparing Same and Its Use
AU1227899A (en) Osmotic medicament releasing system
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
TR200001998T1 (en) Medication formulation to administer controlled release tolterodine
CA2226870A1 (en) Epidural administration of therapeutic compounds with sustained rate of release
HUT56290A (en) Plaster of oestrogenic active ingredient content and method for producing same
CA2298238A1 (en) Controlled release by extrusion of solid amorphous dispersions of drugs
CA2206782A1 (en) Aerosol drug formulations
NO962833L (en) Transdermal preparation comprising polyvinylpyrrolidine
AU1534699A (en) Osmotic dosage form comprising first and second coats
NZ234881A (en) Biphasic transdermal drug delivery device
GB9310412D0 (en) Nasal nicotine system
CA2253980A1 (en) Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
EP1738751A3 (en) Spaced drug delivery system
CA2046014A1 (en) Reduction or prevention of skin irritation by drugs
WO1992002234A3 (en) Reduction or prevention of sensitization to drugs
EP0160501A3 (en) Sustained release intranasal formulation and method of use thereof
YU2494A (en) PHARMACEUTICAL FORMULATION FOR TREATMENT OF NICOTINE SUBSTANCE
IE882898L (en) Solubility modulated drug delivery device
WO1994017792A3 (en) Compositions and methods for transdermal drug delivery
ZA968905B (en) Transdermal therapeutic system (tts) for administering active substances for drug dependence or drug addiction
WO1997018840A3 (en) Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
EP0325086A3 (en) Novel methods for obtaining therapeutic systems with controlled release of the drug
BR9612316A (en) Agent for prophylaxis and treatment of diabetic complications
WO2002030955A3 (en) Tetrapeptide stimulating functional activity of hepatocytes and its therapeutical use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97519955

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA